Alert for Healthcare
Professionals on Galantamine hydrochloride
(marketed as Razadyne, formerly Reminyl)
FDA ALERT [3/2005]: FDA and
other international health authorities are reviewing data from two
studies of Razadyne (galantamine) in the treatment of mild
cognitive impairment because higher mortality rates were seen in
drug-treated patients than placebo-treated patients. Based on
this information, FDA has asked the manufacturer to revise the
labeling.
This information reflects FDA’s
preliminary analysis of data concerning this drug. FDA is
considering, but has not reached a final conclusion about, this
information. FDA intends to update this sheet when additional
information or analyses become available.
To
report any unexpected adverse or serious events associated with the
use of Razadyne, please contact the FDA MedWatch program at
1-800-FDA-1088 or
http://www.fda.gov/medwatch/report/hcp.htm
Recommendations
Available information, including postmarketing data from the
FDA’s Adverse Event Reporting system (AERS) database, does not
warrant changing prescription recommendations at this time. We wish
to emphasize the following:
- Razadyne is approved as a treatment for mild to moderate
Alzheimer’s disease but not for mild cognitive impairment.
Data Summary
Two 2-year trials, involving 2,000 patients in 16 countries,
studied whether Razadyne could slow progression to dementia in
patients with mild cognitive impairment. Individuals with mild
cognitive impairment demonstrate isolated memory impairment greater
than expected for their age and education, but do not meet current
diagnostic criteria for Alzheimer’s disease; however, the majority
of individuals with mild cognitive impairment do appear to develop
overt Alzheimer’s disease over time.
Follow-up information regarding
deaths in these studies is available for about 88 percent of
participants. Fifteen (1.5%) deaths in patients taking Razadyne and
five (0.5%) deaths in patients taking placebo were reported during
the double-blind portion of the two studies, either while taking
study drug/placebo or within 30 days of study drug/placebo
discontinuation. The causes of death in the 20 patients are similar
to those commonly occurring in an older population, and were varied,
with no single cause predominating.
Review of mortality and other safety
data for these two trials is ongoing.
In a number of earlier clinical
trials, none of which lasted longer than 6 months, in similarly-aged
patients (including patients with Alzheimer’s Disease), the
incidence of deaths in those treated with Razadyne was no higher than
in patients treated with placebo, and the incidence of deaths in
those treated with placebo was far higher than in the trials of mild
cognitive impairment, described above.
Report serious adverse events to FDA's MedWatch at
1-800-FDA-1088; or
http://www.fda.gov/medwatch/report/hcp.htm
Questions? Call Drug Information, 1-888-INFO-FDA
(automated) or 301-827-4570
druginfo@fda.hhs.gov
Back
to Top
Back to
Galantamine
Date created: March, 2005, updated August 9, 2006 |